Lv1
48 积分 2023-07-04 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes
6个月前
已完结
IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy
7个月前
已完结
Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease
7个月前
已完结
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer
8个月前
已完结
皖公网安备34019202002308
